Jump Financial’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Jump Financial’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-36,400	Closed	-$149K	–	2269
2023 Q1	$149K	Buy	+36,400	New	+$168K	0.01%	1372
2022 Q4	–	Sell	-31,400	Closed	-$411K	–	2122
2022 Q3	$411K	Buy	31,400 +2,800	+10%	+$42.4K	0.02%	981
2022 Q2	$367K	Buy	28,600 +4,700	+20%	+$65.1K	0.02%	982
2022 Q1	$364K	Sell	23,900 -4,500	-16%	-$70.2K	0.02%	969
2021 Q4	$503K	Buy	28,400 +14,276	+101%	+$274K	0.03%	650
2021 Q3	$297K	Buy	+14,124	New	+$311K	0.02%	672

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jump Financial's NGM Position: Q2 2023 in Review

Jump Financial sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 36,400 shares — an estimated $149K sold.

Jump Financial first reported a position in NGM in Q3 2021 and held it in 6 quarters. The position peaked at $503K in Q4 2021. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

Jump Financial reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Jump Financial sold 36,400 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $149K.
Jump Financial first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Jump Financial's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $503K in Q4 2021.
106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Jump Financial's 13F filing for Q2 2023, filed 7 Aug 2023.